002223 鱼跃医疗
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,370,366-2.69%7,955,0237,565,8197,971,7347,101,679
减:营业总成本1,866,9832.80%6,616,5905,947,0655,804,4265,605,872
    其中:营业成本1,180,164-2.51%3,930,0423,772,2703,877,1863,683,643
               财务费用(7,557)-80.36%(198,976)(235,942)(157,469)(96,253)
               资产减值损失142-252.61%(29,635)(46,990)(92,980)(104,090)
公允价值变动收益--------(4,106)2,160
投资收益2,271196.88%34,15023,206143,208129,132
    其中:对联营企业和合营企业的投资收益(812)96.09%(774)3,08311,82313,219
营业利润501,293-31.97%1,700,3211,931,5812,893,4941,841,804
利润总额501,402-31.98%1,684,4921,932,8292,848,8351,842,418
减:所得税费用72,191-36.63%200,356128,562472,362269,728
净利润429,211-31.13%1,484,1361,804,2662,376,4721,572,690
减:非控股权益883-156.01%2,341(1,434)(19,381)(22,348)
股东净利润428,328-31.44%1,481,7951,805,7012,395,8531,595,037

市场价值指针
每股收益 (元) *0.429-31.57%1.4801.8102.4101.610
每股派息 (元) *----1.0000.8000.8000.600
每股净资产 (元) *13.6164.14%13.20812.50411.7359.836
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容